Cumberland Pharmaceuticals Intends To File New Drug Application To FDA For Ifetroban To Treat Cardiomyopathy Associated With Duchenne Muscular Dystrophy
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its
Cumberland Pharmaceuticals is trying to get a new medicine approved by the FDA. This shows the company is moving forward with treating a serious heart problem in patients with muscular dystrophy.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.